Moderna (MRNA)

=== SEC Form 4 — Statement of Changes in Beneficial Ownership === Document Type: 4 Period of Report: 2026-09-04 10b5-1 Pre-arranged Plan: No --- Issuer --- Name: Moderna, Inc. (MRNA) CIK: 0001682852 --- Reporting Owner --- Name: Klinger Shannon Thyme CIK: 0001866132 Role: Officer (Chief Legal Officer) --- Non-Derivative Transactions --- [Transaction #1] Security: Common Stock Date: 2026-09-04 | Code: M (Exercise of derivative) Shares: +11,797 Shares Owned After: 87,044 | Ownership: D (Direct) Footnotes: [F1] Restricted stock units convert into common stock on a one-for-one basis. [F1] Restricted stock units convert into common stock on a one-for-one basis. [Transaction #2] Security: Common Stock Date: 2026-09-04 | Code: F (Payment of exercise/tax) Shares: -5,704 | Price: $148.87 Total Value: $849,154.48 Shares Owned After: 81,340 | Ownership: D (Direct) Footnotes: [F2] Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. --- Derivative Transactions --- [Transaction #1] Security: Restricted Stock Units Date: 2026-09-04 | Code: M (Exercise of derivative) Shares: -11,797 | Price: $0.00 Shares Owned After: 106,179 | Ownership: D (Direct) Footnotes: [F1] Restricted stock units convert into common stock on a one-for-one basis. [F1] Restricted stock units convert into common stock on a one-for-one basis. [F3] 25% of the shares subject to this restricted stock unit award vested on December 5, 2025, with the remainder vesting in twelve (12) equal quarterly installments thereafter. [F3] 25% of the shares subject to this restricted stock unit award vested on December 5, 2025, with the remainder vesting in twelve (12) equal quarterly installments thereafter. --- Footnotes (Complete Index) --- F1: Restricted stock units convert into common stock on a one-for-one basis. F2: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. F3: 25% of the shares subject to this restricted stock unit award vested on December 5, 2025, with the remainder vesting in twelve (12) equal quarterly installments thereafter. --- Signature --- /s/ /s/ James Dillon, as Attorney-in-Fact (2026-09-08)